All In Biotech

Drug Trial Radar · NCT06676410

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 20, 2023

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Code PharmaIndustry
Sponsor type
Industry
Collaborators
Galilee CBR
First posted
Nov 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. At V0 (W0, D0) all participants will start the antiretroviral treatment described above. From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day). At V6 (W12, D84) treatment with Codivir® will end. At V7 (W24, D168) participation in the study will end. Viral load will be monitored during the study. In case of failure, participation in the study will be discontinued and the participant will be referred to receive the best treatment available for their case.

Conditions

  • HIV
  • HIV Infection

Interventions

  • ICFOther

    Application of Informed Consent Form.

  • Eligibility AssessmentBehavioral

    Assessment of inclusion, exclusion and discontinuation criteria.

  • Demographic dataOther

    Collection of demographic data.

  • Weight, height and BMIDiagnostic test

    Weight and height measurement and body mass index calculation.

  • Vital SignsOther

    HR, BP and FR and T°, in addition to oximetry.

  • Medical evaluationDiagnostic test

    Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.

  • Safety examDiagnostic test

    Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.

  • Pregnancy testDiagnostic test

    β-HCG in urine in non-sterile women

  • SerologyDiagnostic test

    HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).

  • RandomizationOther

    Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group

  • Apoptosis markersDiagnostic test

    Caspases and Annexin V.

  • Cell activation markersDiagnostic test

    PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR

  • Inflammation markersDiagnostic test

    ultrasensitive CRP, D-dimer.

  • Proviral DNA:Diagnostic test

    Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.

  • HIV-specific antibodiesDiagnostic test

    Anti-HIV-1 specific antibody titers in plasma.

  • HIV viral load (RNA)Diagnostic test

    Performed on plasma.

  • Codivir® TrainingBehavioral

    The participant is trained to self-inject Codivir®

  • Dispensing Codivir®Drug

    the participant receives Codivir®

  • Codivir® AccountingOther

    The Codivir® used since the last visit is accounted for

  • Concomitant medicationOther

    Record of concomitant medications used.

  • Adverse eventsOther

    Collection and recording of adverse events.

  • AntiretroviralsDrug

    Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination. * Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro. * Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS. * Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS). * Single solid formulation (in 1 tablet) 1x/day with: * Tenofovir (TDF) 300 mg * Lamivudine (3TC) 300 mg * Darunavir (DRV) 800 mg, 1x/day * Ritonavir (RTV) 100 mg, 1x/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: • Estimated viral reservoir size by total blood proviral DNA.Time frame: 12 weeks
  2. Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: CD4+ blood countTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RDSS Research Center

    São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.